Short interest in Amneal Pharmaceuticals Inc (NASDAQ:AMRX) increased during the last reporting period, rising from 4.89M to 6.10M. This put 3.03% of the company's publicly available shares short.

as well as Amneal's growing injectable portfolio. The new infrastructure is expected to have capacity to produce approximately 250 to 300 million units annually, with potential to scale to more ...

Is your head reeling from all the young royal birthdays? Because, yes, Prince Louis turned 7 at the end of last month, Princess Charlotte turned 10 at the end of last week, and Prince Archie just ...

which could affect the timeline for new product launches. The company is still working towards vertical integration in its biosimilar business, which may take time to fully realize. Amneal ...

Chirag Patel; President, Co-Chief Executive Officer, Co-Founder, Director; Amneal Pharmaceuticals Inc ... since our founding in 2002 in Paterson, New Jersey. Let me now walk you through the ...

Click to share on Facebook (Opens in new window) Click to share on Twitter (Opens in new window) The release of this new family photo comes on the heels of another tumultuous week for Harry and ...

Ayesha Curry shared photos on Instagram showcasing her weekend getaway with her daughter, Riley. The images reveal Riley's growing height, now almost as tall as her mother. Fans reacted to the ...

Amneal’s EPS exceeded expectations by 40%. Revenue growth of 5% year-over-year, despite missing forecasts. Stock price rose 5.04% in premarket trading. Strategic expansion in biosimilars and new ...

Amneal Pharmaceuticals (AMRX) reported $695.42 million in revenue for the quarter ended March 2025, representing a year-over-year increase of 5.5%. EPS of $0.21 for the same period compares to $0. ...